Vertex Pharmaceuticals (VRTX) Convertible Debt (2010 - 2013)

Vertex Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $400.0 million for Q1 2013.

• On a quarterly basis, Convertible Debt changed 0.0% year-over-year to $400.0 million in Q1 2013; TTM through Mar 2013 was $400.0 million, a 0.0% change from a year earlier, with the FY2012 full-year figure at $400.0 million, changed 0.0% from the prior year.
• Convertible Debt was little changed at $400.0 million in Q1 2013 per VRTX's latest filing, from $400.0 million in the prior quarter.
• Across five years, Convertible Debt topped out at $400.0 million in Q3 2010 and bottomed at $32.1 million in Q1 2010.
• The 4-year median for Convertible Debt is $400.0 million (2010), against an average of $366.6 million.
• Biggest YoY gain for Convertible Debt was 1146.11% in 2011; the steepest drop was 0.0% in 2011.
• Year by year, Convertible Debt stood at $400.0 million in 2010, then changed by 0.0% to $400.0 million in 2011, then changed by 0.0% to $400.0 million in 2012, then changed by 0.0% to $400.0 million in 2013.
• Per Business Quant, the three latest VRTX Convertible Debt figures stand at $400.0 million (Q1 2013), $400.0 million (Q4 2012), and $400.0 million (Q3 2012).